| |
| |
|
| Insider
Information: |
Paul Steven M |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
1,185,025 |
|
|
Indirect Shares
|
632,151 |
|
|
| Direct
Value |
$40,560,036 |
|
|
|
Indirect Value
|
$33,183,610 |
|
|
| Total
Shares |
1,817,176 |
|
|
| Total
Value |
$73,743,646 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eli Lilly & Co |
LLY |
EVP, Science and Techn... |
2010-02-01 |
38,897 |
2010-02-01 |
39,040 |
Premium* |
|
|
Sigma-Aldrich Corp |
SIAL |
Director |
2015-11-18 |
0 |
2007-01-02 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2019-03-21 |
272,777 |
2022-11-28 |
593,111 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2022-04-01 |
1,000 |
2015-01-26 |
0 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
President and CEO, Dir... |
2016-01-14 |
872,351 |
|
0 |
Premium* |
|
|
Karuna Therapeutics, Inc. |
KRTX |
|
2024-03-18 |
0 |
2024-03-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
131 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KRTX |
Karuna Therapeutics, Inc. |
PRESIDENT & CEO |
• • – |
2021-08-18 |
4 |
B |
$106.10 |
$125,304 |
I/I |
1,181 |
108,849 |
0.01 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-12-18 |
4 |
OE |
$9.30 |
$139,500 |
D/D |
15,000 |
16,000 |
0 |
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
President and CEO |
• • – |
2016-01-14 |
4 |
B |
$14.07 |
$140,690 |
D/D |
10,000 |
872,351 |
2.81 |
- |
|
| LLY |
Eli Lilly & Co |
officerTitle |
• – – |
2006-02-01 |
4 |
D |
$56.62 |
$158,479 |
D/D |
(2,799) |
95,857 |
|
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2022-04-01 |
4 |
OE |
$11.33 |
$169,950 |
D/D |
15,000 |
16,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-07-31 |
4 |
D |
$54.09 |
$171,087 |
I/I |
(3,163) |
0 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • – |
2014-07-23 |
4 |
B |
$18.00 |
$180,000 |
D/D |
10,000 |
803,650 |
2.39 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
President & CEO |
• • – |
2019-06-28 |
4 |
B |
$22.86 |
$230,424 |
D/D |
10,000 |
10,000 |
2.81 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2019-02-19 |
4 |
AS |
$161.37 |
$249,373 |
I/I |
(1,543) |
72,900 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-02-09 |
4 |
D |
$317.14 |
$254,981 |
D/D |
(804) |
10,596 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-09-27 |
4 |
OE |
$14.66 |
$274,095 |
D/D |
18,700 |
39,204 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2006-10-20 |
4 |
S |
$56.91 |
$275,217 |
I/I |
(4,836) |
1,070 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2019-02-25 |
4 |
AS |
$161.00 |
$322,000 |
I/I |
(2,000) |
70,900 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
officerTitle |
• – – |
2006-02-02 |
4 |
S |
$57.00 |
$353,457 |
D/D |
(6,201) |
89,656 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-02-01 |
4 |
D |
$54.12 |
$378,028 |
D/D |
(6,985) |
64,711 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-03-12 |
4 |
AS |
$52.39 |
$381,871 |
I/I |
(7,289) |
1,070 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-02-12 |
4 |
S |
$54.38 |
$396,430 |
I/I |
(7,290) |
8,359 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2019-03-01 |
4 |
AS |
$161.00 |
$418,600 |
I/I |
(2,600) |
190,700 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-02-10 |
4 |
OE |
$14.67 |
$440,100 |
D/D |
30,000 |
31,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
officerTitle |
• – – |
2005-12-15 |
4 |
OE |
$34.59 |
$453,475 |
D/D |
13,110 |
90,202 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-10-14 |
4 |
OE |
$23.41 |
$461,783 |
D/D |
19,728 |
40,827 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-01-14 |
4 |
A |
$56.79 |
$511,110 |
D/D |
9,000 |
39,818 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-09-27 |
4 |
D |
$63.66 |
$533,853 |
D/D |
(8,386) |
30,818 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-02-08 |
4 |
S |
$54.31 |
$548,234 |
D/D |
(10,092) |
54,619 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2009-02-02 |
4 |
D |
$36.82 |
$567,102 |
D/D |
(15,402) |
42,407 |
0 |
- |
|
131 Records found
|
|
Page 4 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
